Glaucoma

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation for potential treatment of dry AMD, glaucoma, and neurodegenerative eye diseases.

The primary findings were that a higher BMI was protective against glaucoma progression and use of tobacco and alcohol were not significantly associated with retinal nerve fiber layer change.

A retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.

Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.

Puzzle-piecing a new patient’s medical history together takes many forms.

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary end points with no serious adverse events reported in either cohort.

At AAOpt, Dr. Justin Schweitzer talks about myths surrounding ocular surgery and comanagement of surgical patients.

Dr. Justin Schweitzer's 2024 AAOpt talk will cover the latest advancements in ocular drug delivery, including topical, implant, and contact lens-based methods that can improve patient quality of life, adherence, and financial burden.

Julie Rodman, OD, MS, FAAO, details a Rapid Fire session she presented at this year's American Academy of Optometry meeting, which features a case study on retinal vein occlusion.

The study estimated that found approximately 4.22 million people in the US have glaucoma, with as many as 1.49 million people with vision-affecting glaucoma.

As much as 96% of customers and 60% of patients can get their results in less than a minute with Retinalyze, according to the company.

At EyeCon 2024, Analisa Arosemena, MD, discussed the shift away from traditional topical therapies towards more proactive management techniques, aiming to enhance patient outcomes in glaucoma care.

Nathan Lighthizer, OD, FAAO, chats about his various Vision Expo West presentations, including an injections workshop, swollen optic nerve course, and new technology case competition.

Jeffry Gerson, OD, FAAO, gives his golden rules on retinal management in two presentations.

Danica Marrelli, OD, FAAO, AAO Dip, gives advice for those looking to upgrade their OCT or integrate the device into their practice.

Ben Casella, OD, FAAO, chief optometric editor for Optometry Times®, gives a preview of what to expect at this year's EyeCon.

In this episode, four expert faculty talk about the importance of early diagnosis and treatment of thyroid eye disease. They discuss the differential diagnosis, screening tests, and the need for multidisciplinary management for these patients.

Injectsense's future plans for the sensor are to fine-tune its delivery tool and incorporate a microbattery into the sensor.

Taking a contemporary approach to prostaglandin analog therapy.

Recent studies that have reported that active and healthy living can reduce IOP.

Some cases require unorthodox approaches.

Long-term vision and ocular surface health are just part of the puzzle.

Topline results from the trial continue to be expected in H2 2025.

From surgeon to mentor: Smith fuels her commitment to improving glaucoma care by training future ophthalmologists.

FYSX is the first non-pharmacological, non-surgical treatment designed to lower IOP for glaucoma patients, according to a news release.